Logo of brjcancerBJC HomepageBJC Advance online publicationBJC Current IssueSubmitting an article to BJCWeb feeds
Br J Cancer. Jan 2000; 82(2): 368–373.
Published online Jan 18, 2000. doi:  10.1054/bjoc.1999.0928
PMCID: PMC2363300

Number of apoptotic cells as a prognostic marker in invasive breast cancer

Abstract

Apoptosis plays an important role in tumorigenesis. Tumour growth is determined by the rate of cell proliferation and cell death. We counted the number of apoptotic cells in haematoxylin and eosin (H&E)-stained tumour sections in series of 172 grade I and II invasive breast cancers with long-term follow-up. The number of apoptotic cells in ten high-power fields were converted to the number of apoptotic cells per mm2to obtain the apoptotic index (AI). The AI showed a positive correlation to the mitotic activity index (MAI) (P = 0.0001), histological grade (P< 0.0001) and worse tumour differentiation. Patients with high AI showed shorter overall survival than patients with low AI in the total group as well as in the lymph node-positive group. Tumour size, MAI, lymph node status and AI were independent prognostic indicators in multivariate analysis. The AI was shown to be of additional prognostic value to the MAI in the total patients group as well as in the lymph node-positive group. The correlation between the AI and the MAI points to linked mechanisms of apoptosis and proliferation. Since apoptotic cells can be counted with good reproducibility in H&E-stained tumour sections, the AI may be used as an additional prognostic indicator in invasive breast cancer. © 2000 Cancer Research Campaign

Keywords: breast cancer, apoptosis, proliferation, prognostic factor

Full Text

The Full Text of this article is available as a PDF (202K).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Hollowood K, Macartney JC. Reduced apoptotic cell death in follicular lymphoma. J Pathol. 1991 Apr;163(4):337–342. [PubMed]
  • Baak JP, Van Dop H, Kurver PH, Hermans J. The value of morphometry to classic prognosticators in breast cancer. Cancer. 1985 Jul 15;56(2):374–382. [PubMed]
  • Barbareschi M, Caffo O, Veronese S, Leek RD, Fina P, Fox S, Bonzanini M, Girlando S, Morelli L, Eccher C, et al. Bcl-2 and p53 expression in node-negative breast carcinoma: a study with long-term follow-up. Hum Pathol. 1996 Nov;27(11):1149–1155. [PubMed]
  • Bargou RC, Daniel PT, Mapara MY, Bommert K, Wagener C, Kallinich B, Royer HD, Dörken B. Expression of the bcl-2 gene family in normal and malignant breast tissue: low bax-alpha expression in tumor cells correlates with resistance towards apoptosis. Int J Cancer. 1995 Mar 16;60(6):854–859. [PubMed]
  • Berardo MD, Elledge RM, de Moor C, Clark GM, Osborne CK, Allred DC. bcl-2 and apoptosis in lymph node positive breast carcinoma. Cancer. 1998 Apr 1;82(7):1296–1302. [PubMed]
  • Berns EM, Klijn JG, van Putten WL, van Staveren IL, Portengen H, Foekens JA. c-myc amplification is a better prognostic factor than HER2/neu amplification in primary breast cancer. Cancer Res. 1992 Mar 1;52(5):1107–1113. [PubMed]
  • Borg A, Baldetorp B, Fernö M, Olsson H, Sigurdsson H. c-myc amplification is an independent prognostic factor in postmenopausal breast cancer. Int J Cancer. 1992 Jul 9;51(5):687–691. [PubMed]
  • Clayton F. Pathologic correlates of survival in 378 lymph node-negative infiltrating ductal breast carcinomas. Mitotic count is the best single predictor. Cancer. 1991 Sep 15;68(6):1309–1317. [PubMed]
  • Davis PL, Shaiu WL, Scott GL, Iglehart JD, Hsieh TS, Marks JR. Complex response of breast epithelial cell lines to topoisomerase inhibitors. Anticancer Res. 1998 Jul-Aug;18(4C):2919–2932. [PubMed]
  • van Diest PJ, Michalides RJ, Jannink L, van der Valk P, Peterse HL, de Jong JS, Meijer CJ, Baak JP. Cyclin D1 expression in invasive breast cancer. Correlations and prognostic value. Am J Pathol. 1997 Feb;150(2):705–711. [PMC free article] [PubMed]
  • Doglioni C, Dei Tos AP, Laurino L, Chiarelli C, Barbareschi M, Viale G. The prevalence of BCL-2 immunoreactivity in breast carcinomas and its clinicopathological correlates, with particular reference to oestrogen receptor status. Virchows Arch. 1994;424(1):47–51. [PubMed]
  • Evan GI, Wyllie AH, Gilbert CS, Littlewood TD, Land H, Brooks M, Waters CM, Penn LZ, Hancock DC. Induction of apoptosis in fibroblasts by c-myc protein. Cell. 1992 Apr 3;69(1):119–128. [PubMed]
  • Farrow SN, Brown R. New members of the Bcl-2 family and their protein partners. Curr Opin Genet Dev. 1996 Feb;6(1):45–49. [PubMed]
  • Gulli LF, Palmer KC, Chen YQ, Reddy KB. Epidermal growth factor-induced apoptosis in A431 cells can be reversed by reducing the tyrosine kinase activity. Cell Growth Differ. 1996 Feb;7(2):173–178. [PubMed]
  • Heatley MK. Association between the apoptotic index and established prognostic parameters in endometrial adenocarcinoma. Histopathology. 1995 Nov;27(5):469–472. [PubMed]
  • Jannink I, van Diest PJ, Baak JP. Comparison of the prognostic value of four methods to assess mitotic activity in 186 invasive breast cancer patients: classical and random mitotic activity assessments with correction for volume percentage of epithelium. Hum Pathol. 1995 Oct;26(10):1086–1092. [PubMed]
  • de Jong JS, van Diest PJ, Michalides RJ, van der Valk P, Meijer CJ, Baak JP. Correlation of cyclin D1 and Rb gene expression with apoptosis in invasive breast cancer. Mol Pathol. 1998 Feb;51(1):30–34. [PMC free article] [PubMed]
  • Kapucuoglu N, Losi L, Eusebi V. Immunohistochemical localization of Bcl-2 and Bax proteins in in situ and invasive duct breast carcinomas. Virchows Arch. 1997 Jan;430(1):17–22. [PubMed]
  • Krajewski S, Krajewska M, Shabaik A, Miyashita T, Wang HG, Reed JC. Immunohistochemical determination of in vivo distribution of Bax, a dominant inhibitor of Bcl-2. Am J Pathol. 1994 Dec;145(6):1323–1336. [PMC free article] [PubMed]
  • Krajewski S, Blomqvist C, Franssila K, Krajewska M, Wasenius VM, Niskanen E, Nordling S, Reed JC. Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma. Cancer Res. 1995 Oct 1;55(19):4471–4478. [PubMed]
  • Kranenburg O, van der Eb AJ, Zantema A. Cyclin D1 is an essential mediator of apoptotic neuronal cell death. EMBO J. 1996 Jan 2;15(1):46–54. [PMC free article] [PubMed]
  • Leoncini L, Del Vecchio MT, Megha T, Barbini P, Galieni P, Pileri S, Sabattini E, Gherlinzoni F, Tosi P, Kraft R, et al. Correlations between apoptotic and proliferative indices in malignant non-Hodgkin's lymphomas. Am J Pathol. 1993 Mar;142(3):755–763. [PMC free article] [PubMed]
  • van der Linden JC, Baak JP, Lindeman J, Hermans J, Meyer CJ. Prospective evaluation of prognostic value of morphometry in patients with primary breast cancer. J Clin Pathol. 1987 Mar;40(3):302–306. [PMC free article] [PubMed]
  • Lipponen P. Apoptosis in breast cancer: relationship with other pathological parameters. Endocr Relat Cancer. 1999 Mar;6(1):13–16. [PubMed]
  • Lipponen PK, Aaltomaa S. Apoptosis in bladder cancer as related to standard prognostic factors and prognosis. J Pathol. 1994 Aug;173(4):333–339. [PubMed]
  • Lipponen PK, Collan Y, Eskelinen MJ. Volume corrected mitotic index (M/V index), mitotic activity index (MAI), and histological grading in breast cancer. Int Surg. 1991 Oct-Dec;76(4):245–249. [PubMed]
  • Lipponen P, Aaltomaa S, Kosma VM, Syrjänen K. Apoptosis in breast cancer as related to histopathological characteristics and prognosis. Eur J Cancer. 1994;30A(14):2068–2073. [PubMed]
  • Minn AJ, Boise LH, Thompson CB. Bcl-x(S) anatagonizes the protective effects of Bcl-x(L). J Biol Chem. 1996 Mar 15;271(11):6306–6312. [PubMed]
  • Miyashita T, Kitada S, Krajewski S, Horne WA, Delia D, Reed JC. Overexpression of the Bcl-2 protein increases the half-life of p21Bax. J Biol Chem. 1995 Nov 3;270(44):26049–26052. [PubMed]
  • Mustonen M, Raunio H, Päkkö P, Soini Y. The extent of apoptosis is inversely associated with bcl-2 expression in premalignant and malignant breast lesions. Histopathology. 1997 Oct;31(4):347–354. [PubMed]
  • Perego P, Giarola M, Righetti SC, Supino R, Caserini C, Delia D, Pierotti MA, Miyashita T, Reed JC, Zunino F. Association between cisplatin resistance and mutation of p53 gene and reduced bax expression in ovarian carcinoma cell systems. Cancer Res. 1996 Feb 1;56(3):556–562. [PubMed]
  • van de Schepop HA, de Jong JS, van Diest PJ, Baak JP. Counting of apoptotic cells: a methodological study in invasive breast cancer. Clin Mol Pathol. 1996 Aug;49(4):M214–M217. [PMC free article] [PubMed]
  • Sierra A, Castellsagué X, Coll T, Mañas S, Escobedo A, Moreno A, Fabra A. Expression of death-related genes and their relationship to loss of apoptosis in T1 ductal breast carcinomas. Int J Cancer. 1998 Apr 17;79(2):103–110. [PubMed]
  • Sjöström J, Krajewski S, Franssila K, Niskanen E, Wasenius VM, Nordling S, Reed JC, Blomqvist C. A multivariate analysis of tumour biological factors predicting response to cytotoxic treatment in advanced breast cancer. Br J Cancer. 1998 Sep;78(6):812–815. [PMC free article] [PubMed]
  • van Slooten HJ, van de Vijver MJ, van de Velde CJ, van Dierendonck JH. Loss of Bcl-2 in invasive breast cancer is associated with high rates of cell death, but also with increased proliferative activity. Br J Cancer. 1998 Mar;77(5):789–796. [PMC free article] [PubMed]
  • Staunton MJ, Gaffney EF. Apoptosis: basic concepts and potential significance in human cancer. Arch Pathol Lab Med. 1998 Apr;122(4):310–319. [PubMed]
  • Uyterlinde AM, Schipper NW, Baak JP, Peterse H, Matze E. Limited prognostic value of cellular DNA content to classical and morphometrical parameters in invasive ductal breast cancer. Am J Clin Pathol. 1988 Mar;89(3):301–307. [PubMed]
  • Veronese S, Mauri FA, Caffo O, Scaioli M, Aldovini D, Perrone G, Galligioni E, Doglioni C, Dalla Palma P, Barbareschi M. Bax immunohistochemical expression in breast carcinoma: a study with long term follow-up. Int J Cancer. 1998 Feb 20;79(1):13–18. [PubMed]
  • Wijsman JH, Jonker RR, Keijzer R, van de Velde CJ, Cornelisse CJ, van Dierendonck JH. A new method to detect apoptosis in paraffin sections: in situ end-labeling of fragmented DNA. J Histochem Cytochem. 1993 Jan;41(1):7–12. [PubMed]
  • Yang E, Korsmeyer SJ. Molecular thanatopsis: a discourse on the BCL2 family and cell death. Blood. 1996 Jul 15;88(2):386–401. [PubMed]
  • Zhang GJ, Kimijima I, Abe R, Watanabe T, Kanno M, Hara K, Tsuchiya A. Apoptotic index correlates to bcl-2 and p53 protein expression, histological grade and prognosis in invasive breast cancers. Anticancer Res. 1998 May-Jun;18(3B):1989–1998. [PubMed]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

Formats:

Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...

Links

  • MedGen
    MedGen
    Related information in MedGen
  • PubMed
    PubMed
    PubMed citations for these articles

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...